Question 1

Should I switch from Saxenda to Wegovy?

Accepted Answer

For most patients, yes. The STEP-8 head-to-head trial (Rubino 2022 JAMA, PMID 35015037) randomized 338 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg over 68 weeks. Wegovy produced -15.8% body weight vs Saxenda's -6.4% — a 9.4-percentage-point gap, plus less-frequent injection burden. Most clinicians start Wegovy at 0.25 mg weekly regardless of prior Saxenda dose since the molecules have different half-lives and no dose-equivalence is established. Insurance prior auth may require documented inadequate response on Saxenda before approving Wegovy.

Question 2

Why does insurance still cover Saxenda when Wegovy is more effective?

Accepted Answer

Two reasons. First, Saxenda was approved earlier (December 2014) and is locked into many plan formularies as the step-therapy prerequisite — patients must fail Saxenda before Wegovy is authorized. Second, despite Saxenda's higher retail price (~$1,400/mo vs Wegovy's ~$1,350 list), insurance plans negotiate rebates differently and some still favor Saxenda for legacy contracting reasons. Pediatric coverage also differs at the state-Medicaid level — a few state Medicaid programs cover Saxenda (12+ approval date 2020) but exclude Wegovy (12+ approval date 2022).

Question 3

Is daily injection really worse than weekly?

Accepted Answer

Functionally, yes — adherence data consistently shows weekly GLP-1s have ~15-25% better persistence at one year than daily versions, mostly because patients forget or skip daily doses. The clinical magnitude is also different: in STEP-8 (Rubino 2022 JAMA), Wegovy beat Saxenda by 9.4 percentage points of body weight — far larger than what a missed-dose-adherence gap alone would predict. The pharmacology matters too: semaglutide's ~7-day half-life produces stable receptor occupancy, while liraglutide's ~13-hour half-life means daily peaks and troughs that may produce more day-to-day GI symptom variability.

Question 4

Can pregnant patients planning conception use Saxenda for the shorter washout?

Accepted Answer

Possibly — but discuss with a maternal-fetal specialist first. Both Wegovy and Saxenda carry the same pregnancy guidance: discontinue at least 2 months before a planned pregnancy. The mechanistic difference is washout speed — liraglutide's ~13-hour half-life means it clears in 2-3 days, while semaglutide's ~7-day half-life requires 5-7 weeks for full washout. For patients with unplanned-pregnancy risk or rapid conception timelines, Saxenda's shorter washout offers a margin of safety. Neither drug has prospective human pregnancy outcome data, and both are categorized as not recommended in pregnancy.

Question 5

Will my insurance stop covering Wegovy if Saxenda failed?

Accepted Answer

Usually it's the opposite — most commercial plans require documented inadequate response (typically <5% weight loss over 12-16 weeks) on a covered GLP-1 like Saxenda before approving Wegovy, since Wegovy is more expensive and more recently approved. Failure on Saxenda is generally a step-therapy unlock, not a disqualifier. The clinical rationale: Saxenda and Wegovy share the same GLP-1 mechanism, but the molecules are different (liraglutide vs semaglutide) and STEP-8 demonstrated semaglutide produces ~2.5x the weight loss at maximum dose. Document your Saxenda trial duration, peak dose tolerated, and percent weight change to streamline the prior authorization.

Question 6

Do Saxenda and Wegovy have the same side effects?

Accepted Answer

The profiles overlap heavily — both are dominated by gastrointestinal effects (nausea, diarrhea, constipation, vomiting). In STEP-8, GI adverse events occurred in 84% of Wegovy patients vs 83% of Saxenda patients; serious adverse events were similar (4% vs 3%). Both carry the same FDA boxed warning for thyroid C-cell tumors based on rodent data. The main practical difference is symptom rhythm: Saxenda's daily dosing produces daily GI peaks, while Wegovy's weekly dosing produces a more spread-out tolerability curve. Pancreatitis, gallbladder disease, and acute kidney injury via dehydration are shared rare risks.

Field	Wegovy	Saxenda
Head-to-head (STEP-8, 68 weeks)	-15.8% body weight (semaglutide 2.4 mg weekly)	-6.4% body weight (liraglutide 3.0 mg daily)
Mechanism	GLP-1 receptor agonist (long-acting, ~7-day half-life)	GLP-1 receptor agonist (short-acting, ~13-hour half-life)
Dosing frequency	Once-weekly subcutaneous injection	Once-daily subcutaneous injection
Cardiovascular outcome	MACE -20% (SELECT, 2023, obesity without diabetes)	No dedicated obesity CVOT; LEADER (T2D, liraglutide 1.8 mg) showed MACE -13%
Pivotal obesity trial	STEP-1: -14.9% TBWL at 68 weeks	SCALE Obesity: -8.0% TBWL at 56 weeks
Cash price (manufacturer cash-pay program)	$349-$499/mo via NovoCare manufacturer cash-pay program	~$1,400/mo retail; no comparable manufacturer cash-pay program
FDA-approved indications	Chronic weight management; cardiovascular risk reduction (March 2024)	Chronic weight management (adults + pediatric ≥12)
Pediatric availability (≥12 years)	Approved December 2022 (ages 12+, BMI ≥95th percentile)	Approved December 2020 (ages 12+, body weight >60 kg + BMI ≥95th percentile)

Wegovy vs Saxenda (2026): STEP-8 Head-to-Head, Cost, Dosing

The verdict

Side-by-side comparison

Frequently asked questions